Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh (JNJB34) Price & Analysis

Q: Is Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh overvalued?

According to Wall Street analysts Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Which hedge fund is a major shareholder of Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh?

Currently, no hedge funds are holding shares in BR:JNJB34

― Followers

JNJB34 Stock Chart & Stats

R$93.60

-R$0.31(-0.33%)

Aug 20, 2026

―

Day’s Range― - ―

52-Week RangeR$61.56 - R$95.08

Previous CloseN/A

VolumeN/A

Average Volume (3M)9.87K

Market Cap

R$3.42T

Enterprise ValueR$3.34M

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)31303.3

Beta-0.18

Next Earnings

Oct 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)<0.01

Shares Outstanding36,148,465,000

10 Day Avg. Volume11,768

30 Day Avg. Volume9,866

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh News

Protagonist Therapeutics price target raised to $178 from $112 at BMO Capital

BMO Capital raised the firm’s price target on Protagonist Therapeutics (PTGX) to $178 from $112 and keeps an...

4d ago

JNJ

PTGX

Oppenheimer upgrades Intuitive Surgical on lack of U.S. competition

Oppenheimer upgraded Intuitive Surgical (ISRG) to Outperform from Perform with a $500 price target. Field checks suggest workflow...

4d ago

JNJ

ISRG

Oppenheimer downgrades Legend Biotech to Perform on CEO/competition overhangs

As previously reported, Oppenheimer downgraded Legend Biotech (LEGN) to Perform from Outperform with a $40 price target. Following...

4d ago

JNJ

LEGN

Trump Trade: President signs EO to split up of childhood vaccines

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

10d ago

AZN

EBS

Trump signs EO to split up of childhood vaccines, Bloomberg reports

President Donald Trump signed an executive order proposing to split the MMR vaccine into separate shots, require separate...

11d ago

AZN

EBS

Protagonist Therapeutics price target raised to $173 from $118 at Wedbush

Wedbush raised the firm’s price target on Protagonist Therapeutics (PTGX) to $173 from $118 and keeps an Outperform...

11d ago

JNJ

PTGX

Trump Trade: U.S. issues 15% duty on products made from polysilicon

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

14d ago

AZN

EBS

Trump admin plans to issue executive order on vaccines, autism, Bloomberg says

Trump administration is planning to issue an executive order on vaccines and autism next week, prompted by the...

14d ago

AZN

EBS

Johnson & Johnson price target raised to $287 from $270 at Guggenheim

Guggenheim raised the firm’s price target on Johnson & Johnson to $287 from $270 and keeps a Buy...

15d ago

JNJ

Zymeworks price target raised to $51 from $46 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Zymeworks (ZYME) to $51 from $46 and keeps a Buy...

16d ago

JNJ

JAZZ

JNJ’s OTTAVA Robotics and Medtech Strategy Underpin Buy Rating and Unchanged $282 Price Target

Analyst Asad Haider of Goldman Sachs reiterated a Buy rating on Johnson & Johnson, retaining the price target...

17d ago

JNJ

Ottava Robotic Platform and MedTech Upside Underscore Buy Rating on JNJ with Unchanged $294 Price Target

Analyst Terence Flynn of Morgan Stanley maintained a Buy rating on Johnson & Johnson, retaining the price target...

17d ago

JNJ

Johnson & Johnson: Talc Settlement Progress Removes Major Overhang; Buy Rating Reiterated with Unchanged $282 Price Target

Johnson & Johnson, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Asad Haider...

24d ago

JNJ

Johnson & Johnson: Talc Settlement Progress Supports Buy Rating with Unchanged $294 Price Target

Terence Flynn, an analyst from Morgan Stanley, maintained the Buy rating on Johnson & Johnson. The associated price...

24d ago

JNJ

JNJB34 FAQ

What was Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s price range in the past 12 months?

Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh lowest stock price was R$61.56 and its highest was R$95.08 in the past 12 months.

What is Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s market cap?

Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s market cap is R$3.42T.

When is Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s upcoming earnings report date?

Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s upcoming earnings report date is Oct 20, 2026 which is in 60 days.

How were Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s earnings last quarter?

Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh released its earnings results on Jul 15, 2026. The company reported R$0.001 earnings per share for the quarter, beating the consensus estimate of N/A by R$0.001.

Is Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh overvalued?

According to Wall Street analysts Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh pay dividends?

Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh does not currently pay dividends.

What is Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s EPS estimate?

Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh have?

Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh has 36,148,465,000 shares outstanding.

What happened to Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh’s price movement after its last earnings report?

Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh reported an EPS of R$0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.777%.

Which hedge fund is a major shareholder of Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh?

Currently, no hedge funds are holding shares in BR:JNJB34

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology